# Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)
Canonical URL: https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-announces-advancement-of-its-zelicapavir-clinical-development-program-for-the-treatment-of-respiratory-syncytial-virus-rsv
Ticker: ENTA
Company: Enanta Pharmaceuticals
Source: Enanta Pharmaceuticals
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.enanta.com
## Summary

Registrational Ph2b/3 Trial of Zelicapavir to Initiate in High-Risk Adults with RSV in 4Q 2026, with Topline Phase 2b Data Expected in 2027 Phase 2b Trial of Zelicapavir to Initiate in Pediatric Patients with RSV in 3Q 2026, with Topline Data Expected in 2027 WATERTOWN, Mass.

## Article Body
Registrational Ph2b/3 Trial of Zelicapavir to Initiate in High-Risk Adults with RSV in 4Q 2026, with Topline Phase 2b Data Expected in 2027 Phase 2b Trial of Zelicapavir to Initiate in Pediatric Patients with RSV in 3Q 2026, with Topline Data Expected in 2027 WATERTOWN, Mass.
## Recent Company News
- 2026-06-25 13:46 EST — [Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus](https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-partner-abbvie-receives-european-commission-approval-of-maviretr-glecaprevir-pibrentasvir-for-people-with-acute-hepatitis-c-virus) — Source: Enanta Pharmaceuticals
- 2026-06-25 13:46 EST — [Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)](https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-announces-advancement-of-its-zelicapavir-clinical-development-program-for-the-treatment-of-respiratory-syncytial-virus-rsv) — Source: Enanta Pharmaceuticals
- 2026-06-25 13:46 EST — [Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-to-present-at-the-jefferies-global-healthcare-conference) — Source: Enanta Pharmaceuticals
- 2026-06-25 13:46 EST — [Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026](https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-second-quarter-ended-march-31-2026) — Source: Enanta Pharmaceuticals
- 2026-06-25 13:46 EST — [Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025](https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-fourth-quarter-and-year-ended-september-30-2025) — Source: Enanta Pharmaceuticals
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)